{"title":"皮肤毒性蚂蚁抗EGFR治疗：老年人和体弱Mcrc患者的一个模拟问题","authors":"R. Addeo","doi":"10.26420/annhematoloncol.2018.1213","DOIUrl":null,"url":null,"abstract":"prognosis and survival. co morbidity advanced most clinical trials sufficient on the appropriate management of elderly patients with metastatic CRC. The development of new therapeutic agents bevacizumab (anti-VRGF) and cetuximab panitumumab (anti-Epidermal Growth Factor Receptor (EGFR)) which target specific molecular events in tumour cells provides new opportunities to improve the treatment of this type of cancer.","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Skin Toxicity Ant Anti-EGFR-Therapy: A Mock Trouble for Elderly and Frail Patients with Mcrc\",\"authors\":\"R. Addeo\",\"doi\":\"10.26420/annhematoloncol.2018.1213\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"prognosis and survival. co morbidity advanced most clinical trials sufficient on the appropriate management of elderly patients with metastatic CRC. The development of new therapeutic agents bevacizumab (anti-VRGF) and cetuximab panitumumab (anti-Epidermal Growth Factor Receptor (EGFR)) which target specific molecular events in tumour cells provides new opportunities to improve the treatment of this type of cancer.\",\"PeriodicalId\":72219,\"journal\":{\"name\":\"Annals of hematology & oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of hematology & oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26420/annhematoloncol.2018.1213\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hematology & oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26420/annhematoloncol.2018.1213","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Skin Toxicity Ant Anti-EGFR-Therapy: A Mock Trouble for Elderly and Frail Patients with Mcrc
prognosis and survival. co morbidity advanced most clinical trials sufficient on the appropriate management of elderly patients with metastatic CRC. The development of new therapeutic agents bevacizumab (anti-VRGF) and cetuximab panitumumab (anti-Epidermal Growth Factor Receptor (EGFR)) which target specific molecular events in tumour cells provides new opportunities to improve the treatment of this type of cancer.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
